Advanced Enzyme Technologies share news, announcements and annual reports
NSE: ADVENZYMESBSE: 540025Pharmaceuticals & BiotechnologySmall Cap
Advanced Enzyme Technologies Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2016 · Issue price ₹896
Last close ₹263.55down ₹0.60 (0.23%)BSE ₹262.95
Share price at the NSE close on 30 Oct 2026. Previous close ₹264.15.
30 Oct: open ₹266.00, high ₹268.05, low ₹259.50
52-week range of traded prices to 30 Oct 2026
₹246.80Low, 26 Oct 2026₹419.00High, 11 May 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,929 Cr912th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 17.14
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.76
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.51%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,81,29158.4% delivered
Advanced Enzyme Technologies share news and announcements
743 announcements, routine notices left out, newest first. Page 15 of 15.
Feb 2017
28 Feb · Analysts
20 Feb · Disclosure
15 Feb · Analysts
14 Feb · Legal
Exchange has sought clarification from Advanced Enzyme Technologies Limited with respect to announcement dated 14-Feb-2017, regarding "Advanced Enzyme Technologies Limited has informed the Exchange that the Board of Directors in its Meeting held on February 14, 2017 has deputed Mr. Prabal Bordiya, existing Company Secretary and Compliance Officer as Company Secretary of JC Bio Tech Private Limited a Subsidiary Company with effect from February 13, 2017. In his place Mr. Sanjay Basantani is appointment as 'Company Secretary & Head Legal' and 'Compliance Officer' of the Company with effect from February 14, 2017 pursuant to Section 203 of the Companies Act, 2013 and Regulation 6 (1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.14 Feb · Analysts
14 Feb · Board meeting
14 Feb · Results
10 Feb · Analysts
Dec 2016
14 Dec · Legal
Exchange has sought clarification from Advanced Enzyme Technologies Limited with respect to announcement dated 14-Dec-2016, that the Board of Directors have approved by Circular Resolution dated on December 14, 2016 appointment of Mr. Pramod Kasat as an Independent Non-Executive Director as an additional director on the Board of Directors of the Company, who shall hold office upto the date of the next General Meeting of the Company.On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);2. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.12 Dec · Analysts
1 Dec · Business
1 Dec · Others
Nov 2016
29 Nov · Analysts
29 Nov · Analysts
24 Nov · Updates
22 Nov · Analysts
16 Nov · Utilisation of Funds
16 Nov · Analysts
15 Nov · Analysts
14 Nov · Results
10 Nov · Analysts
Oct 2016
28 Oct · Analysts
28 Oct · Analysts
28 Oct · Board meeting
Sep 2016
21 Sep · Analysts
20 Sep · Analysts
19 Sep · Regulation 44(3) of SEBI (LODR), Reg., 2015
15 Sep · Board meeting
Aug 2016